abstract |
Novel substituted heterocyclic compounds, compositions containing them, and methods of using the same to inhibit Raf kinase activity are provided. The novel compounds and compositions can be used alone or in combination with one or more additional agents for the treatment of Raf kinase mediated disorders, such as cancer. |